Document is current
Any future updates will be listed below
-
Authors
Chen, Wei
Martinez, Lyndsey T.
Falcao, Larissa
Li, Zhenghui
McKeen, Andrew P.
Kurhade, Chaitanya
Boigard, Hélène
Roopchand, Vidia
Richardson, Imani
Dasgupta, Trisha
Llamera, Katrina E.
Colatat, Jing
Brock, Linda Goding
Anderson, Annaliesa S.
Swanson, Kena A.
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 26 September 2025
Accepted: 24 February 2026
First Online: 14 March 2026
Competing interests
: All authors are current or former employees of Pfizer Inc. and may be shareholders and/or hold stock options. Pfizer participated in the design, analysis and interpretation of the data as well as the writing of this report and the decision to publish. K.A.S. is an inventor on patents related to the RSVpreF vaccine. K.A.S., A.S.A., and W.C. are inventors on patents related to nucleic acid methodology or formulations for vaccines against RSV and/or other respiratory viruses.
